Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009.
Genentech became a wholly owned subsidiary group of Roche on 25 March 2009. [27] ... at $74 a share this represents a 38% premium over the final share closing price, ...
From 2017 to 2018, he was the CEO of Genentech. [6] While at Genentech, he developed its immunology and ophthalmology divisions, managed the sales of Rituxan, Raptiva, and Xolair, and directed Roche's late-stage portfolio committee for nearly four years, where he was responsible for determining late-stage clinical trial advancements. [6]
Get breaking Business News and the latest corporate happenings from AOL. From analysts' forecasts to crude oil updates to everything impacting the stock market, it can all be found here.
But Genentech -- which had all the features of a Technology Leader (about. Swiss pharma giant Roche has reached an agreement with Genentech (DNA) to acquire at $95 a share the other 44 percent of ...
For starters, Oppenheimer pointed out that the speed of the recent rises in stock prices likely reflects much of the good news that Wall Street is expecting on growth in 2025.
Valeant raised its unsolicited offer for Allergan a second time, to $53.3 billion, increasing the cash portion of the bid in an effort to win the backing of the company, with the cash-and-stock portion of the bid valuing each Allergan share at $179.25. [26] 16 2014 Valeant Pharmaceuticals: Allergan, Inc: 49.4 64
Click here for in-depth analysis of the latest stock market news and events moving stock prices. Read the latest financial and business news from Yahoo Finance. Show comments. Advertisement.